Yanyong Xu
Shanghai Medical College of Fudan University(CN)Ministry of Education(KR)
Publications by Year
Research Areas
Liver Disease Diagnosis and Treatment, Cholesterol and Lipid Metabolism, Adipokines, Inflammation, and Metabolic Diseases, Peroxisome Proliferator-Activated Receptors, Drug Transport and Resistance Mechanisms
Most-Cited Works
- → Macrophage miR-34a Is a Key Regulator of Cholesterol Efflux and Atherosclerosis(2019)122 cited
- → Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR(2018)114 cited
- → Mouse models of atherosclerosis in translational research(2022)95 cited
- → Hepatocyte Nuclear Factor 4α Prevents the Steatosis‐to‐NASH Progression by Regulating p53 and Bile Acid Signaling (in mice)(2020)82 cited
- → Hepatocyte ATF3 protects against atherosclerosis by regulating HDL and bile acid metabolism(2021)81 cited
- → Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease(2021)71 cited
- → Narirutin activates TFEB (transcription factor EB) to protect against Acetaminophen-induced liver injury by targeting PPP3/calcineurin(2023)62 cited
- → FABP5+ lipid-loaded macrophages process tumour-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity(2024)60 cited
- → Prenatal caffeine exposure increases the susceptibility to non-alcoholic fatty liver disease in female offspring rats via activation of GR-C/EBPα-SIRT1 pathway(2019)53 cited
- → Hepatocytic Activating Transcription Factor 3 Protects Against Steatohepatitis via Hepatocyte Nuclear Factor 4α(2021)35 cited